Justification of Intensive care management of children with severe COVID19 (а case study)

  • Roman Tkachuk Bukovinian State Medical University, Chernivtsi, Ukraine; Regional Municipal Non-Profit Facility «Chernivtsi Regional Children's Clinical Hospital», Chernivtsi, Ukraine https://orcid.org/0000-0002-6753-2365
  • Olena Koloskova Bukovinian State Medical University, Chernivtsi, Ukraine http://orcid.org/0000-0002-4402-8756
  • Mykola Garas Bukovinian State Medical University, Chernivtsi, Ukraine http://orcid.org/0000-0001-7304-2090
  • Tetyana Bilous Bukovinian State Medical University, Chernivtsi, Ukraine http://orcid.org/0000-0002-9469-401X
  • Iryna Gurina Regional Municipal Non-Profit Facility «Chernivtsi Regional Children's Clinical Hospital», Chernivtsi, Ukraine
  • Andii Polishchuk Regional Municipal Non-Profit Facility «Chernivtsi Regional Children's Clinical Hospital», Chernivtsi, Ukraine
  • Viktoriia Antoniichuk Municipal non-profit enterprise "Chernivtsi Regional Bureau of Forensic Medicine", Chernivtsi, Ukraine https://orcid.org/0000-0002-6281-8647
Keywords: Children, COVID-19, Therapy, Pneumonia, Pneumothorax, severe аcute respiratory distress syndrome, intensive therapy, remdesivir

Abstract

the unprecedented COVID-19 pandemic that spread across the world and lasted for more than 3 years had significant medical and social consequences. Despite the fact that in the children's population the coronavirus infection has a milder course and a much lower risk of mortality, there are individual cases with pre-existing comorbidities that cause severe acute respiratory distress syndrome. Thus, in most cases, severe COVID-19 developed in children with pre-existing conditions, including: immunodeficiency, diabetes mellitus, bronchial asthma, etc. Therefore, comorbidities disposed children to progress to severe Covid-19 which requires treatments with more aggressive therapeutic tactics and personalised management. The article presents a clinical case of severe acute respiratory distress syndrome caused by the SARS-CoV-2 virus in an early age child. The patient was observed in the Anesthesiology and Intensive Therapy Department of the Chernivtsi Regional Children's Clinical Hospital. Due to acute respiratory infection, the child has been developing signs of respiratory failure. The available instrumental findings confirmed right lung pneumonia, complicated by pneumothorax. Laboratory tests confirmed leukocytosis, thrombocytopenia, hypertransfusion, increased procalcitonin, increased level of C-reactive protein, D-dimer and interleukin-6 as well as circulating immune complexes. The treatment regimen included respiratory protection (oxygen therapy), support of hemodynamics (infusion of glucose-saline solutions), administration of intravenous normal human immunoglobulin, a short course of parenteral glucocorticosteroids, the use of step-by-step combined antibacterial therapy and a direct-acting antiviral drug (remdesivir), and thromboembolism prophylaxis (low-molecular-weight heparin). Following intensive treatment, the child's condition was characterised by a slow positive dynamics, leading to full recovery. This case demonstrates the need for timely detection of life-threatening conditions caused by COVID-19 and requires an aggressive management of child's condition using a complex intensive therapy.

References

Bihm, D., Huang, J., et al (2023). Safety of Tocilizumab and Remdesivir in Treating COVID-19 Pneumonia in Premature Twins. Pediatrics, 151(4), e2022058196. https://doi.org/10.1542/peds.2022-058196
Chera, A., & Tanca, A. (2022). Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children. Discoveries (Craiova, Romania), 10(2), e151. https://doi.org/10.15190/d.2022.10
Esposito, S., Abate, L., et al (2021). COVID-19 in Children: Update on Diagnosis and Management. Seminars in respiratory and critical care medicine, 42(6), 737–746. https://doi.org/10.1055/s-0041-1741371
Madani, S., Shahin, S., et al (2021). Red flags of poor prognosis in pediatric cases of COVID-19: the first 6610 hospitalized children in Iran. BMC pediatrics, 21(1), 563. https://doi.org/10.1186/s12887-021-03030-2
Mahler, M., Meroni, P. L., et al (2021). Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert review of clinical immunology, 17(5), 431–443. https://doi.org/10.1080/1744666X.2021.1905526
Наказ МОЗ України №762 від 02.02.2020 р. про затвердження протоколу «Надання медичної допомоги для лікування коронавірусної хвороби (COVID-19)» зі змінами та доповненнями.
Sahi, P. K., Jhamb, U., et al (2021). Pediatric Coronavirus Disease 2019: Clinical Features and Management. Indian pediatrics, 58(5), 453–460. https://doi.org/10.1007/s13312-021-2216-4
Saleh, N. Y., Aboelghar, H. M., et al (2021). The severity and atypical presentations of COVID-19 infection in pediatrics. BMC pediatrics, 21(1), 144. https://doi.org/10.1186/s12887-021-02614-2
Published
2024-03-28
How to Cite
Tkachuk, R., Koloskova , O., Garas , M., Bilous , T., Gurina , I., Polishchuk , A., & Antoniichuk, V. (2024). Justification of Intensive care management of children with severe COVID19 (а case study). The Ukrainian Scientific Medical Youth Journal, 144(1), 208-215. Retrieved from http://mmj.nmuofficial.com/index.php/journal/article/view/37